deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT03943147

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis

Sponsor: Bristol-Myers Squibb

Conditions Lupus Nephritis
Interventions BMS-986165 Mycophenolate Mofetil Placebo
Updated 24 times since 2019 Last updated: Sep 16, 2022 Started: Jul 15, 2019 Primary completion: Oct 29, 2020 Completion: Sep 17, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Insufficient enrollment

Other terminated trials from Bristol-Myers Squibb

See all terminations from Bristol-Myers Squibb

Other Lupus Nephritis trials with similar outcome

Browse all Lupus Nephritis trials

A PHASE2 clinical study on Lupus Nephritis, this trial is terminated or withdrawn. The trial is conducted by Bristol-Myers Squibb and has accumulated 24 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Nov 2022 · 7 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 9 months · monthly snapshot

Change History

24 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Nov 2022 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 19 earlier versions

  1. Apr 2022 — Nov 2022 [monthly]

    Terminated PHASE2

  2. Dec 2021 — Apr 2022 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  7. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  8. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  9. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  10. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  11. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  12. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  13. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  14. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  15. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  16. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  17. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  18. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  19. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Augusta, United States , Aurora, United States , Baltimore, United States , Barcelona, Spain , Bethlehem, United States , Birmingham, United States , Brighton, United Kingdom , Brighton, United States , Busan, South Korea and 74 more locations